BRCA2 and ovarian cancer: Initial studies soon after the discovery of BRCA2 reported consistent inactivation of the wild‐type BRCA2 allele through loss‐of‐heterozygosity (LOH) in breast or ovarian cancer cells from mutation carriers (Collins et al., 1995; Gudmundsson et al., 1995), engendering the widely accepted view that BRCA2 LOH is an essential event in carcinogenesis.